Immuneering Corporation (IMRX) Misses Q4 EPS by 13c

Immuneering Corporation (NASDAQ: IMRX) reported Q4 EPS of ($0.58), $0.13 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Immuneering Corporation (IMRX) click here.

You May Also Be Interested In

• Envista Holdings (NVST) Reiterated at Buy by Stifel on Raised Mid-Term Objectives
• Early Warning Press Release Disposition by Stephanie Sparks in NamSys Inc.
• HubSpot (HUBS) Reiterated at Hold by Stifel Amid Top-Line Uncertainty